Compare iShares China Large-Cap ETF (FXI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares China Large-Cap ETF trades at $34.59, while Zimmer Biomet Holdings Inc trades at $93.01 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares China Large-Cap ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | ZBH | |
|---|---|---|
52-Week High | $41.75 | $107.71 |
52-Week Low | $31.59 | $79.58 |
Market Cap | — | $17.44B |
Sector | — | Health |
Enterprise Value | — | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
